Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders.
Prospective surveillance studies to monitor drug safety in the postapproval period are rarely employed systematically, although they are of greatest value for caregivers, drug users and regulatory authorities. Safety issues have affected not only conventional pharmaceuticals, but also especially coagulation factors in haemophilia treatment. The reputation of postmarketing surveillance (PMS) studies has been questionable, mainly due to their misuse to solicit prescriptions. Other weaknesses include inappropriate design, lack of standardized observation, limited follow-up periods, absence of rigour in identifying potential adverse drug effects, and infrequent publication. Although well-designed clinical trials represent the gold standard for generating sound clinical evidence, a number of aspects would make PMS studies valuable, if properly conducted. One of their main advantages is broader inclusion, and absence of an 'experimental' design. Lack of proper guidelines, and standardization may constitute a reason for the generally low quality of PMS studies. This paper proposes guidelines for haemophilia-specific PMS studies, in order to improve the acceptance of a basically valuable tool. In the absence of consistent regulatory guidance it will be especially important that the design and supervision of PMS studies involves physicians from the beginning. This will not only make such studies more scientifically relevant, but also help to implement them into daily clinical practice. Specifically in haemophilia, PMS studies may provide valuable data on clinical outcomes, or Quality of Life, which is of great importance when considering adequate standards of care in haemophilia patients.
Lassila
R
R
Department of Haematology, Coagulation Disorders, Helsinki University Central Hospital, Helsinki, Finland. riitta.lassila@hus.fi
Rothschild
C
C
De Moerloose
P
P
Richards
M
M
Perez
R
R
Gajek
H
H
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000009:adverse effects; D017408:Guidelines as Topic; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D011788:Quality of Life; D012107:Research Design; D012307:Risk Factors; D012449:Safety; D016896:Treatment Outcome
D001779:Blood Coagulation Factors